Literatur
- 1 Lambert M, Naber D. Pharmakotherapie der Schizophrenie. Taschenatlas spezial. Stuttgart;
Thieme 2009
- 2 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde DGPPN.
Leitlinienprojektgruppe: W. Gaebel (federführend), P. Falkai, S. Weinmann, T. Wobrock
.S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 – Behandlungsleitlinie
Schizophrenie. Darmstadt; Steinkopff-Verlag 2006
- 3
Cheung H K.
Schizophrenics fully remitted on neuroleptics for 3–5 years – to stop or continue
drugs?.
Br J Psychiatry.
1981;
138
490-494
- 4
Davis J M, Andriukaitis S.
The natural course of schizophrenia and effective maintenance drug treatment.
J Clin Psychopharmacol.
1986;
6 (1 Suppl.)
2-10
- 5
Gilbert P L, Harris M J, McAdams L A. et al .
Neuroleptic withdrawal in schizophrenic patients. A review of the literature.
Arch Gen Psychiatry.
1995;
52
173-188
- 6
Gitlin M, Nuechterlein K, Subotnik K L. et al .
Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset
schizophrenia.
Am J Psychiatry.
2001;
158
1835-1842
- 7
Kane J M.
Schizophrenia.
N Engl J med.
1996;
334
34-41
- 8
Lehman A F, Steinwachs D M.
Evidence-based psychosocial treatment practices in schizophrenia: lessons from the
patient outcomes research team (PORT) project.
J Am Acad Psychoanal Dyn Psychiatry.
2003;
31
141-154
- 9
Leucht S, Barnes T R, Kissling W. et al .
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic
review and exploratory meta-analysis of randomized, controlled trials.
Am J Psychiatry.
2003;
160
1209-1222
- 10 NICE .Schizophrenia: Core interventions in the treatment and management of schizophrenia
in adults in primary and secondary care. NICE clinical guideline 82, Developed by
the National Collaborating Centre for Mental Health. Issue date March 2009 http://guidance.nice.org.uk/CG82/NICEGuidance/pdf/English
- 11
Falkai P, Wobrock T, Lieberman J. et al., WFSBP Task Force on Treatment Guidelines
for Schizophrenia .
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological
treatment of schizophrenia, part 2: long-term treatment of schizophrenia.
World J Biol Psychiatry.
2006;
7
5-40
- 12
Meltzer H Y, Lee M A, Ranjan R. et al .
Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.
Psychopharmacology (Berl).
1996;
124
176-187
- 13
Tenback D E, van Harten P N, Slooff C J. et al .
Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia.
J Psychopharmacol.
2010;
24
1031-1035
- 14
Smith M, Hopkins D, Peveler R C. et al .
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia:
systematic review and meta-analysis.
Br J Psychiatry.
2008;
192
406-411
- 15
Weinmann S, Read J, Aderhold V.
Influence of antipsychotics on mortality in schizophrenia: systematic review.
Schizophr Res.
2009;
113
1-11
- 16
Tiihonen J, Lönnqvist J, Wahlbeck K. et al .
11-year follow-up of mortality in patients with schizophrenia: a population-based
cohort study (FIN11 study).
Lancet.
2009;
374
620-627
- 17
Viguera A C, Baldessarini R J, Hegarty J D. et al .
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
Arch Gen Psychiatry.
1997;
54
49-55
- 18
Yamauchi K, Aki H, Tomotake M. et al .
Predictors of subjective and objective quality of life in outpatients with schizophrenia.
Psychiatry Clin Neurosci.
2008;
62
404-411
Dr. med. Alkomiet Hasan
Zentrum für Psychosoziale Medizin
Abteilung für Psychiatrie und Psychotherapie
Universitätsmedizin Göttingen
Von-Siebold-Straße 5
37075 Göttingen
eMail: ahasan@gwdg.de
Priv.-Doz. Dr. med. Thomas Wobrock
Zentrum für Psychosoziale Medizin
Abteilung für Psychiatrie und Psychotherapie
Universitätsmedizin Göttingen
Von-Siebold-Straße 5
37075 Göttingen
eMail: twobroc@gwdg.de
